Valuation : vTv Therapeutics Inc.

Market Cap 414M 357M 335M 306M 573M 39.12B 575M 3.96B 1.54B 20.07B 1.56B 1.52B 64.66B P/E 2026 *
-15.6x
P/E 2027 * -8.13x
Enterprise Value 414M 357M 335M 306M 573M 39.12B 575M 3.96B 1.54B 20.07B 1.56B 1.52B 64.66B EV / Sales 2026 *
14.9x
EV / Sales 2027 * -
Free-Float
61.17%
Yield 2026 *
-
Yield 2027 * -
1 week+2.92%
Current month+3.68%
1 month+3.68%
3 months-2.08%
6 months-6.62%
Current year-10.19%
1 week 27
Extreme 27
28.2
1 month 25.4
Extreme 25.4
30
Current year 24
Extreme 24
37.2
1 year 15.6
Extreme 15.6
37.2
3 years 11.12
Extreme 11.12
37.2
5 years 11.12
Extreme 11.12
75.2
10 years 11.12
Extreme 11.12
262
Manager TitleAgeSince
Chief Executive Officer 68 2022-07-31
Director of Finance/CFO 50 2025-05-18
Chief Tech/Sci/R&D Officer - 2023-11-01
Director TitleAgeSince
Director/Board Member 56 2020-11-15
Director/Board Member 48 2022-07-10
Chairman 68 2024-02-29
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+2.92% - - 414M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.24%+0.26%+42.70%+177.58% 31.01B
Weighted average by Cap. -1.52%+0.18%+38.37%+137.35%

Financials

2026 *2027 *
Net sales 27.9M 24.01M 22.59M 20.63M 38.6M 2.63B 38.71M 267M 104M 1.35B 105M 102M 4.35B -
Net income -26.7M -22.97M -21.61M -19.74M -36.94M -2.52B -37.04M -255M -99.11M -1.29B -100M -98.06M -4.17B -63.19M -54.37M -51.16M -46.73M -87.42M -5.97B -87.66M -605M -235M -3.06B -237M -232M -9.86B
Net Debt - -
Logo vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Employees
26
Date Price Change
26-09-04 €28.20 0.00%
26-09-03 €28.20 +4.44%
26-09-02 €27.00 0.00%
26-09-01 €27.00 -0.74%
26-08-31 €27.20 -0.73%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
33.35USD
Average target price
54.71USD
Spread / Average Target
+64.06%

Quarterly revenue - Rate of surprise